Guidance for Xeris Pharmaceuticals Inc. (XERS)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $380.00M – 390.00M | $383.30M | = Maintained | Details |
| 2026 | N/A | N/A | $375.00M – 390.00M | $368.00M | = Maintained | Details |
| 2025 | N/A | N/A | $285.00M – 290.00M | $286.50M | = Maintained | Details |
| 2025 | N/A | N/A | $280.00M – 290.00M | $269.40M | = Maintained | Details |
| 2025 | N/A | N/A | $260.00M – 270.00M | $262.30M | = Maintained | Details |
| 2025 | N/A | N/A | $255.00M – 275.00M | $239.80M | = Maintained | Details |
| 2024 | N/A | N/A | $198.00M – 202.00M | $193.40M | = Maintained | Details |
| 2024 | N/A | N/A | $190.00M – 200.00M | $187.30M | = Maintained | Details |
| 2024 | N/A | N/A | $175.00M – 200.00M | $184.40M | = Maintained | Details |
| 2024 | N/A | N/A | $170.00M – 200.00M | $184.10M | = Maintained | Details |
| 2023 | N/A | N/A | $135.00M – 165.00M | $146.90M | = Maintained | Details |
| 2023 | N/A | N/A | $135.00M – 165.00M | $152.30M | = Maintained | Details |
| 2022 | N/A | N/A | $105.00M – 120.00M | N/A | = Maintained | Details |
